Impact of Cannabinoids on Menopause Symptoms
Completed · Phase 2 · Has a placebo group
Conditions studied: Perimenopause, Menopause
In brief
The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Key facts
- Study ID
- NCT06831916
- Run by
- Washington State University
- People needed
- 104
- Starts
- 2025-03-03
- Expected to finish
- 2025-10-30
- Last updated by the study team
- 2026-06-02
Who can join
Age: 40 and older, up to 60. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- designated female at birth
- 40-60 years of age
- able to give informed consent (no intellectual disability)
- stable pharmacotherapeutic regimen, no change in the past 3 months
- abstinent from regular cannabis use (<1x/month) for past year, and willing to abstain from use for 3 months
- abstinent for supplements, don't add any supplements (no changes in past 3 months)
- own a smartphone
- have access to Zoom on a secure, stable internet connection
- perimenopausal or menopausal
You may not qualify if…
- currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication
- severe depression, neurovegetative symptoms, or current suicidality
- psychosis or family history of psychosis
- pregnant or breastfeeding
- chemotherapy
- hypotension
- drug testing for work or other reasons
- illicit drug use in past 3 months (cannabis not illicit)
- heavy alcohol use (4 drinks more than 4x/week)
- international/air travel planned for more than one week in the next 3 months
Where it is running
- Washington State University - Pullman Campus — Pullman, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.